2016 Hematological Malignancies

HD13: Progression-free survival All patients (ITT)

0.0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1.0

5 year estimate [95%-CI] median observation time

2xABVD+IF: 2xABV+IF: 2xAVD+IF:

93.3% [90.9% to 95.6%] 82.0% [76.6% to 87.5%] 89.0% [86.1% to 91.9%] 80.6% [74.7% to 86.5%]

53 m 83 m 55 m 82 m

PFS

2xAV+IF:

ABVD

ABV

AVD

AV

0

12

24

36

48

60

72

Time [months]

Pts. at Risk

ABVD ABV AVD AV

623 209 620 186

593 189 592 166

556 178 540 153

490 170 477 144

362 156 344 128

228 139 230 118

130 109 126 93